Skip to main content

Clinical assessment of PILA PHARMA’s TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent

Project description

Bringing a novel anti-diabetic drug to the clinic

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

PILA PHARMA AB
Net EU contribution
€ 50 000,00
Address
Vastergatan 1
211 21 Malmo
Sweden

See on map

Region
Södra Sverige Sydsverige Skåne län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 21 429,00